~~<i id='E2EB473040'><strike id='E2EB473040'><tt id='E2EB473040'><pre id='E2EB473040'></pre></tt></strike></i>~~

Home» comprehensive» comprehensive

comprehensive

author：hotspot 2025-09-29 21:37:08 Page View：63815

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why a market frenzy over new weight loss drugs defies logic
Next article： Alkermes shareholders re

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Merck, Daiichi strike cancer drug pact worth up to $22 billion

KenaBetancur/GettyImagesMADRID—MerckispayingbillionsofdollarstopartnerwithDaiichiSankyoonaseriesofca

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

JasonBuenrostroinhisHarvardlab.CourtesyJohnD.andCatherineT.MacArthurFoundationTheyoungestofthisyear’

WSS

comprehensive

comprehensive

explore

leisure time

Harvard's Jason Buenrostro wins MacArthur grant for genetics work